Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pheochromocytoma × Everolimus × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Breast Neoplasms 44 Carcinoma, Renal Cell 25 Neoplasm Metastasis 15 Neoplasms 13 Kidney Neoplasms 11 Neuroendocrine Tumors 10 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Melanoma 6 Lymphoma 6 Tuberous Sclerosis 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Glioma 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Astrocytoma 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Neurofibromatosis 2 3

Interventions

lutetium Lu 177 dotatate 4 Temozolomide 4 Specimen Handling 3 3-Iodobenzylguanidine 3 olaparib 2 belzutifan 2 anlotinib 2 Magnetic Resonance Spectroscopy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 tipifarnib 1 talazoparib 1 penpulimab 1 pazopanib 1 lenvatinib 1 lanreotide 1 guadecitabine 1 gallium Ga 68 dotatate 1 fostamatinib 1 copper dotatate CU-64 1 cabozantinib 1 atezolizumab 1 Ritonavir 1 Radiotherapy 1 Octreotide 1 Nivolumab 1 Melphalan 1 Lutetium-177 1 Lutetium 1 Ipilimumab 1 Indinavir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01152827 2015-05-20

PheoCarcRAD001

Seoul National University Hospital

Phase 2 Completed

Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡